The quantification of new infections to determine parasite viability offers important advantages over existing methods, and is amenable to medium–high throughput screening.
The delays in seeking treatment, the type of malaria therapy received and the cost of treatment are the principal problems found in Bata District.
The ongoing development of new antimalarial drugs and the increasing use of controlled human malaria infection (CHMI) studies to investigate their activity in early-stage clinical trials require the development of methods to analyze their pharmacodynamic effect.
The production of cultured P. falciparum blood-stage malaria cell banks represents a suitable approach for the generation of material suitable for CHMI studies.
Flow cytometric detection of Hz allowed the detection of drug effects in blood samples from malaria patients, without using additional reagents or complex protocols.
The SYBR green I modified protocol produced reliable results and could be a suitable method for in vitro/ex vivo assays in field.
Plasmodium falciparum has the capacity to escape the actions of essentially all antimalarial drugs.
The Plasmodium liver stage is an attractive target for the development of antimalarial drugs and vaccines, as it provides an opportunity to interrupt the life cycle of the parasite at a critical early stage.
The Shoklo Malaria Research Unit has been working on the Thai–Myanmar border for 25 y providing early diagnosis and treatment (EDT) of malaria.
Dehydroepiandrosterone (DHEA) inhibits glucose 6-phosphate dehydrogenase (G6PDH) of different species and may potentially decrease intracellular glutathione.